Eur Arch Otorhinolaryngol:非特发性突发感音神经性听力损失患者比特发性突发感音神经性听力损失患者更常表现出听力情况的改善

2021-03-31 AlexYang MedSci原创

最近,有研究人员比较了住院治疗的特发性(ISSNHL)和非特发性突发感音神经性听力损失(NISSNHL)患者在频率、听力损失、治疗和效果方面的情况。

最近,有研究人员比较了住院治疗的特发性(ISSNHL)和非特发性突发感音神经性听力损失(NISSNHL)患者在频率、听力损失、治疗和效果方面的情况

研究人员回顾性地纳入了2011年和2012年接受治疗的574名ISSNHL和NISSNHL住院患者(51%为男性,中位年龄:60岁)。结果表明,490名患者(85%)诊断为ISSNHL,84名患者(15%)诊断为NISSNHL。其中49%的病例因急性中耳炎导致听力损失,37%通过水痘-带状疱疹感染或莱姆病导致听力损失,10%通过梅尼埃病导致听力损失,7%因其他原因导致听力损失。

ISSNHL和NISSNHL患者的年龄、性别、听力损失的单侧位置、是否有耳鸣或眩晕及其合并症之间没有差异。45%的ISSNHL和62%的NISSNHL患者在住院治疗前曾接受过门诊治疗(P<0.001)。ISSNHL从听力损失发生到住院治疗的平均间隔时间(7.7天)比NISSNHL(8.9天;p=0.02)短。纯音平均(3PTAmax)中三个最易受影响的初始听力损失频率在ISSNHL中为72.9 dBHL±31.3 dBHL,在NISSNHL中为67.4 dBHL±30.5 dBHL。在急性中耳炎情况中,3PTAmax(59.7 dBHL±24.6 dBHL)低于水痘-带状疱疹感染或莱姆病(80.11 dBHL±34.19 dBHL;p=0.015)。ISSNHL患者的平均绝对听力增益(Δ3PTAmaxabs)为8.1 dB±18.8 dB,NISSNHL患者为10.2 dB±17.6 dB,且没有差异。ISSNHL患者中34.3%的患者达到Δ3PTAmaxabs≥10 dB,NISSNHL患者中达到更高的比例48.8%(P=0.011)。

最后,研究人员指出,ISSNHL和NISSNHL没有显示出相关基线差异。ISSNHL往往具有较高的初始听力损失。NISSHNL显示出比ISSNHL更好的结果

原始出处:

Jovanna Thielker , Anne Heuschkel , Daniel Boeger et al. Patients with non-idiopathic sudden sensorineural hearing loss show hearing improvement more often than patients with idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. Mar 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894798, encodeId=4eb41894e98fb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jun 30 06:33:03 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035487, encodeId=12aa203548e56, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Mon Jun 28 17:33:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306644, encodeId=c0b41306644c6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 02 11:33:03 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894798, encodeId=4eb41894e98fb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jun 30 06:33:03 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035487, encodeId=12aa203548e56, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Mon Jun 28 17:33:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306644, encodeId=c0b41306644c6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 02 11:33:03 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894798, encodeId=4eb41894e98fb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jun 30 06:33:03 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035487, encodeId=12aa203548e56, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Mon Jun 28 17:33:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306644, encodeId=c0b41306644c6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 02 11:33:03 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
    2021-04-02 ysjykql

相关资讯

盘点:近期鼻炎与治疗进展(五)

【1】ORL J Otorhinolaryngol Relat Spec:富血小板血浆注射液对萎缩性鼻炎患者的影响

Sci Rep:前列腺切除术后尿失禁的新型治疗方法:富含血小板血浆尿道括约肌注射

富含血小板的血浆(PRP)是再生医学中最具创新性的血源性产品。

盘点:近期听力损失与治疗进展(五)

【1】Ear Nose Throat J:羟基磷灰石假体在耳硬化症病例中的应用

Eur Urol:前列腺动脉栓塞术与经尿道前列腺切除术治疗良性前列腺增生效果比较

继发于良性前列腺梗阻(LUTS/BPO)的下尿路症状的前列腺动脉栓塞术(PAE)治疗仍在研究中。

Eur Arch Otorhinolaryngol:鼓膜硬化症的内窥镜下经外耳道治疗

最近,有研究人员描述他们在内镜下经耳道治疗鼓膜硬化症的经验,解释了他们重建声音传导系统的手术方法,并分析了手术方法所获得的听力效果。

盘点:近期前列腺癌与治疗进展(五)

【1】Eur Urol:前列腺手术后男性尿道压力性尿失禁手术的非劣效性随机对照试验结果(MASTER)